Research

Hormonal

Semaglutide 2.4 mg weekly produces significant weight loss (14.9% reduction) in individuals with obesity.

Semaglutide 2.4 mg is a once-weekly injection approved for chronic weight management. It significantly reduces body weight by mimicking the GLP-1 hormone, which helps control appetite. Common side effects include gastrointestinal issues, which often improve over time.

GoodSupportsHIGH confidence
In STEP 1, Semaglutide users achieved a 14.9% weight reduction compared to 2.4% in the placebo group at week 68 (ETD: −12.4%; 95% CI: −13.4% to −11.5%; P < 0.001).
Wael R. Sidrak et al. · Indian Journal of Endocrinology and Metabolism · 2024

Why this rating

Based on STEP 1, a phase III RCT with significant results.

Source

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article

Wael R. Sidrak et al. · Indian Journal of Endocrinology and Metabolism · 2024

DOI 10.4103/ijem.ijem_442_23

narrative_reviewCited 15×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →